Patent: 9,233,171
✉ Email this page to a colleague
Summary for Patent: 9,233,171
Title: | Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate |
Abstract: | The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed. |
Inventor(s): | Setiady; Julianto (Waltham, MA), Park; Peter U. (Somerville, MA), Chittenden; Thomas (Sudbury, MA) |
Assignee: | ImmunoGen, Inc. (Waltham, MA) |
Application Number: | 13/682,948 |
Patent Claims: | see list of patent claims |
Details for Patent 9,233,171
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2031-11-21 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2031-11-21 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2031-11-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |